Mode
Text Size
Log in / Sign up
N/A N=10 Treatment

WallFlex Biliary Post Liver Transplant IDE Pilot

Anastomotic Biliary Stricture Post Orthotopic Liver Transplant

Enrolled (actual)
10
Serious AEs
60.0%
Results posted
Jul 2013
Primary outcome: Primary: Stricture Resolution at the Time of Stent Removal. — 9; 1 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
WallFlex Biliary Fully Covered Stent (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Boston Scientific Corporation
Primary completion
Oct 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Stricture Resolution at the Time of Stent Removal.
9; 1
SECONDARY
Safety
2; 2; 0
SECONDARY
Stent Removability
9; 1
SECONDARY
Technical Success of Stent Placement
10; 0
SECONDARY
Effectiveness of Stent at 6 Months
6; 2; 1
SECONDARY
Re-intervention Occurrence
4; 2; 2; 1; 1
SECONDARY
Time to Stent Occlusion
68

Summary

The primary objective of this study is to demonstrate effectiveness of the WallFlex Biliary RX Fully Covered Stent for anastomotic biliary strictures in post-orthotopic liver transplant (OLT) patients.

Eligibility Criteria

Inclusion Criteria

  • Age 18 or older
  • Post -OLT patients with symptoms of biliary obstruction secondary to anastomotic biliary stricture as assessed by:
  • Clinical signs and symptoms including jaundice, abdominal pain, pruritis, and cholangitis
  • Abnormal liver function tests (serum bilirubin > 1.5 and/or elevated alkaline phosphatase levels)
  • Abnormal imaging on ultrasound, CT scan, or MRCP suggestive of a biliary stricture
  • Willingness and ability to comply with the study procedures and provide written informed consent to participate in the study.

Exclusion Criteria

  • Roux-en-Y choledochojejunostomy
  • Suspected nonanastomotic biliary strictures based on imaging(i.e. multiple strictures, strictures that are longer than 8cm in length, strictures located in the intrahepatic ducts and/or in the donor duct proximal to the site of anastomosis)
  • Living donor transplants
  • Transplants performed within 30 days (fresh transplants)
  • Perforation of any duct within the biliary tree
  • Patients with known sensitivity to any components of the stent or delivery system
  • Patients with malignancy involving the biliary tree (including hepatocellular carcinoma)
  • Patients with poor Karnofsky score
  • Life expectancy of less than one year
  • Inability to pass a guidewire through the strictured area
  • Previous biliary metal or multiple plastic stent placement
  • Drug-induced or cholestatic hepatitis from an infective cause
  • Redundant bile duct that may be treated by temporary placement of stent or conversion to a RouxEnY hepaticojejunostomy
  • Choledocholithiasis/biliary "cast" syndrome
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01151280). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search